| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IDXX Overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
IDEXX Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$651.96 |
| 52 Week High | US$419.12 |
| 52 Week Low | US$706.95 |
| Beta | 0.95 |
| 1 Month Change | -4.07% |
| 3 Month Change | -6.27% |
| 1 Year Change | 47.12% |
| 3 Year Change | 210.13% |
| 5 Year Change | 527.01% |
| Change since IPO | 68,867.71% |
Recent News & Updates
These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Potentially Undervalued?
Let's talk about the popular IDEXX Laboratories, Inc. ( NASDAQ:IDXX ). The company's shares received a lot of attention...
Shareholder Returns
| IDXX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.7% | 3.6% | 1.9% |
| 1Y | 47.1% | 23.8% | 33.4% |
Return vs Industry: IDXX exceeded the US Medical Equipment industry which returned 23.8% over the past year.
Return vs Market: IDXX exceeded the US Market which returned 33.4% over the past year.
Price Volatility
| IDXX volatility | |
|---|---|
| IDXX Beta | 0.95 |
| Industry Beta | 0.88 |
| Market Beta | 1 |
Stable Share Price: IDXX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: IDXX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 9,300 | Jay Mazelsky | https://www.idexx.com |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
IDEXX Laboratories Fundamentals Summary
| IDXX fundamental statistics | |
|---|---|
| Market Cap | US$55.47b |
| Earnings (TTM) | US$727.85m |
| Revenue (TTM) | US$3.05b |
76.2x
P/E Ratio18.2x
P/S RatioIs IDXX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDXX income statement (TTM) | |
|---|---|
| Revenue | US$3.05b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$1.79b |
| Expenses | US$1.06b |
| Earnings | US$727.85m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 02, 2021
| Earnings per share (EPS) | 8.56 |
| Gross Margin | 58.83% |
| Net Profit Margin | 23.89% |
| Debt/Equity Ratio | 121.0% |
How did IDXX perform over the long term?
See historical performance and comparisonValuation
Is IDEXX Laboratories undervalued compared to its fair value and its price relative to the market?
76.21x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IDXX ($651.96) is trading above our estimate of fair value ($305.88)
Significantly Below Fair Value: IDXX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IDXX is poor value based on its PE Ratio (76.2x) compared to the US Medical Equipment industry average (50x).
PE vs Market: IDXX is poor value based on its PE Ratio (76.2x) compared to the US market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: IDXX is poor value based on its PEG Ratio (6.9x)
Price to Book Ratio
PB vs Industry: IDXX is overvalued based on its PB Ratio (74.2x) compared to the US Medical Equipment industry average (4.2x).
Future Growth
How is IDEXX Laboratories forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
11.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDXX's forecast earnings growth (11% per year) is above the savings rate (2%).
Earnings vs Market: IDXX's earnings (11% per year) are forecast to grow slower than the US market (14.7% per year).
High Growth Earnings: IDXX's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDXX's revenue (9.1% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: IDXX's revenue (9.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDXX's Return on Equity is forecast to be very high in 3 years time (55.9%).
Past Performance
How has IDEXX Laboratories performed over the past 5 years?
23.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDXX has high quality earnings.
Growing Profit Margin: IDXX's current net profit margins (23.9%) are higher than last year (18.6%).
Past Earnings Growth Analysis
Earnings Trend: IDXX's earnings have grown significantly by 23.6% per year over the past 5 years.
Accelerating Growth: IDXX's earnings growth over the past year (58.2%) exceeds its 5-year average (23.6% per year).
Earnings vs Industry: IDXX earnings growth over the past year (58.2%) exceeded the Medical Equipment industry 36.1%.
Return on Equity
High ROE: Whilst IDXX's Return on Equity (97.32%) is outstanding, this metric is skewed due to their high level of debt.
Financial Health
How is IDEXX Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: IDXX's short term assets ($1.0B) exceed its short term liabilities ($651.8M).
Long Term Liabilities: IDXX's short term assets ($1.0B) do not cover its long term liabilities ($1.0B).
Debt to Equity History and Analysis
Debt Level: IDXX's debt to equity ratio (121%) is considered high.
Reducing Debt: IDXX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IDXX's debt is well covered by operating cash flow (85.1%).
Interest Coverage: IDXX's interest payments on its debt are well covered by EBIT (28.2x coverage).
Balance Sheet
Dividend
What is IDEXX Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDXX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDXX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IDXX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Jay Mazelsky (60 yo)
2.33yrs
Tenure
US$7,038,175
Compensation
Mr. Jonathan J. Mazelsky, also known as Jay, has been President, Chief Executive Officer and Director at IDEXX Laboratories, Inc. since October 23, 2019. Mr. Mazelsky was an Interim President and Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD7.04M) is below average for companies of similar size in the US market ($USD11.15M).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: IDXX's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: IDXX's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IDXX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
IDEXX Laboratories, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: IDEXX Laboratories, Inc.
- Ticker: IDXX
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$55.466b
- Shares outstanding: 85.08m
- Website: https://www.idexx.com
Number of Employees
Location
- IDEXX Laboratories, Inc.
- One IDEXX Drive
- Westbrook
- Maine
- 4092
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/26 22:30 |
| End of Day Share Price | 2021/10/26 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.